A subtype specific probe for targeted magnetic resonance imaging of M2 tumor-associated macrophages in brain tumors
Source abstract
Abstract
Pro-tumoral M2 tumor-associated macrophages (TAMs) play a critical role in the tumor immune microenvironment (TIME), making them an important therapeutic target for cancer treatment. Approaches for imaging and monitoring M2 TAMs, as well as tracking their changes in response to tumor progression or treatment are highly sought-after but remain underdeveloped. Here, we report an M2-targeted magnetic resonance imaging (MRI) probe based on sub-5 nm ultrafine iron oxide nanoparticles (uIONP), featuring an anti-biofouling coating to prevent non-specific macrophage uptake and an M2-specific peptide ligand (M2pep) for active targeting of M2 TAMs. The targeting specificity of M2pep-uIONP was validated in vitro, using M0, M1, and M2 macrophages, and in vivo, using an orthotopic patient-tissue-derived xenograft (PDX) mouse model of glioblastoma (GBM). MRI of the mice revealed hypointense contrast in T 2 -weighted images of intracranial tumors 24 hours after receiving intravenous (i.v.) injection of M2pep-uIONP. In contrast, no noticeable change in contrast was observed in mice receiving scrambled-sequence M2pep-conjugated uIONP (scM2pep-uIONP) or the commercially available iron oxide nanoparticle formulation, Ferumoxytol. Measurement of nanoparticle-induced T 2 value changes in tumors showed 38%, 9%, and 2% decrease for M2pep-uIONP, scM2pep-uIONP, and Ferumoxytol, respectively. Moreover, M2pep-uIONP exhibited 88.7-fold higher intra-tumoral accumulation compared to co-injected Ferumoxytol at 24 hours post-injection. Immunofluorescence-stained tumor sections showed that CD68 + /CD163 + M2 TAMs were highly co-localized with Cy7-M2pep-uIONP, but not with Cy7-scM2pep-uIONP and Cy7-Ferumoxytol. Flow cytometry analysis revealed 26 ± 10% of M2 TAMs were targeted by M2pep-uIONP, which was significantly higher than Ferumoxytol (16 ± 1%) and scM2pep-uIONP (13 ± 4%) with the same dosage (20 mg Fe/kg). These findings demonstrate that M2pep-uIONP functions as a ligand-mediated MRI probe for targeted imaging of M2 TAMs in GBM, with potential applications for imaging of M2 TAM in other cancer types. Targeting the pro-tumoral M2 subtype of tumor-associated macrophages (TAMs) to modulate the tumor immune microenvironment (TIME) is an emerging strategy for developing novel cancer therapies and enhancing the efficacy of existing treatments. In this study, we have developed a magnetic resonance imaging (MRI) probe using sub-5 nm ultrafine iron oxide nanoparticles (uIONP), which are coated with an anti-biofouling polymer and conjugated to an M2-specific peptide ligand (M2pep). Our results demonstrate that M2pep-uIONP exhibits an 88.7-fold higher accumulation in intracranial tumors in an orthotopic patient-derived xenograft (PDX) model of glioblastoma compared to the commercial iron oxide nanoparticle, Ferumoxytol. This enhanced accumulation enables M2pep-uIONP to induce significant MRI contrast, providing a non-invasive imaging tool to visualize M2 TAMs and monitor changes in the TIME of brain tumors and potentially other cancers.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Immune cells in cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (80)
Show source-provided references
1. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth10.1016/j.ccell.2023.02.016 ↗
2. Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy10.1172/JCI163446 ↗
3. Metabolic rewiring of macrophages by CpG potentiates clearance of cancer cells and overcomes tumor-expressed CD47− mediated ‘don't-eat-me'signal10.1038/s41590-018-0292-y ↗
4. Mechanisms of immunotherapy resistance: lessons from glioblastoma10.1038/s41590-019-0433-y ↗
5. Tumor associated macrophages, as the dominant immune cells, are an indispensable target for immunologically cold tumor—glioma therapy?10.3389/fcell.2021.706286 ↗
6. Hacking macrophage-associated immunosuppression for regulating glioblastoma angiogenesis10.1016/j.biomaterials.2018.01.053 ↗
7. TGF-β1 secreted by M2 phenotype macrophages enhances the stemness and migration of glioma cells via the SMAD2/3 signalling pathway
8. M2 macrophage-targeted iron oxide nanoparticles for magnetic resonance image-guided magnetic hyperthermia therapy10.1016/j.jmst.2020.11.058 ↗
9. The yin and yang of imaging tumor associated macrophages with PET and MRI10.7150/thno.37306 ↗
10. MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles10.1158/1078-0432.CCR-10-3420 ↗
11. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD10.2215/CJN.05320513 ↗
12. Current and potential imaging applications of ferumoxytol for magnetic resonance imaging10.1016/j.kint.2016.12.037 ↗
13. Distinguishing extravascular from intravascular ferumoxytol pools within the brain: proof of concept in patients with treated glioblastoma10.3174/ajnr.A6600 ↗
14. Quantification of macrophages in high-grade gliomas by using ferumoxytol-enhanced MRI: a pilot study10.1148/radiol.2018181204 ↗
15. Ferumoxytol nanoparticle uptake in brain during acute neuroinflammation is cell-specific10.1016/j.nano.2016.03.009 ↗
16. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues10.1038/nnano.2016.168 ↗
17. The story of ferumoxytol: synthesis production, current clinical applications, and therapeutic potential10.1002/adhm.202302773 ↗
18. Nanoparticle uptake: the phagocyte problem10.1016/j.nantod.2015.06.006 ↗
19. Tailoring nanomaterials for targeting tumor-associated macrophages10.1002/adma.201808303 ↗
20. Differential uptake of nanoparticles by human M1 and M2 polarized macrophages: protein corona as a critical determinant10.2217/nnm-2016-0233 ↗
21. PEG-b-AGE polymer coated magnetic nanoparticle probes with facile functionalization and anti-fouling properties for reducing non-specific uptake and improving biomarker targeting10.1039/C4TB01828A ↗
22. Improving sensitivity and specificity of capturing and detecting targeted cancer cells with anti-biofouling polymer coated magnetic iron oxide nanoparticles10.1016/j.colsurfb.2016.10.026 ↗
23. Targeted imaging of CD206 expressing tumor-associated M2-like macrophages using mannose-conjugated antibiofouling magnetic iron oxide nanoparticles10.1021/acsabm.0c00368 ↗
24. Targeted Delivery of DNA topoisomerase inhibitor SN38 to intracranial tumors of glioblastoma using sub-5 ultrafine iron oxide nanoparticles
25. Brain tumor imaging and delivery of sub-5 nm magnetic iron oxide nanoparticles in an orthotopic murine model of glioblastoma10.1021/acsanm.2c01930 ↗
26. Probing and enhancing ligand-mediated active targeting of tumors using sub-5 nm ultrafine iron oxide nanoparticles10.7150/thno.39560 ↗
27. Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival10.1073/pnas.1312197110 ↗
28. Molecular-targeted immunotherapeutic strategy for melanoma via dual-targeting nanoparticles delivering small interfering RNA to tumor-associated macrophages10.1021/acsnano.7b05465 ↗
29. Facile non-hydrothermal synthesis of oligosaccharide coated sub-5 nm magnetic iron oxide nanoparticles with dual MRI contrast enhancement effects10.1039/C4TB00811A ↗
30. Heat-induced radiolabeling and fluorescence labeling of Feraheme nanoparticles for PET/SPECT imaging and flow cytometry10.1038/nprot.2017.133 ↗
31. Exerting enhanced permeability and retention effect driven delivery by ultrafine iron oxide nanoparticles with T1–T2 switchable magnetic resonance imaging contrast10.1021/acsnano.7b00038 ↗
32. Bioconjugated manganese dioxide nanoparticles enhance chemotherapy response by priming tumor-associated macrophages toward M1-like phenotype and attenuating tumor hypoxia10.1021/acsnano.5b06779 ↗
33. Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ10.1016/j.celrep.2012.12.013 ↗
34. Delineation of MGMT hypermethylation as a biomarker for veliparib-mediated temozolomide-sensitizing therapy of glioblastoma
35. Cell detection with star-convex polygons
36. Star-convex polyhedra for 3D object detection and segmentation in microscopy
37. Nuclei instance segmentation and classification in histopathology images with stardist
38. SciPy 1.0: fundamental algorithms for scientific computing in Python10.1038/s41592-019-0686-2 ↗
39. In-situ vaccination using dual responsive organelle targeted nanoreactors10.1016/j.biomaterials.2022.121843 ↗
40. M2pep-modified cyclodextrin-siRNA nanoparticles modulate the immunosuppressive tumor microenvironment for prostate cancer therapy10.1021/acs.molpharmaceut.3c00769 ↗
41. Modification of MR molecular imaging probes with cysteine-terminated peptides and their potential for in vivo tumour detection10.1002/cmmi.403 ↗
42. Improving sensitivity and specificity of amyloid-β peptides and tau protein detection with antibiofouling magnetic nanoparticles for liquid biopsy of Alzheimer's disease10.1021/acsbiomaterials.9b00086 ↗
43. Core cross-linked polymeric micelles for specific iron delivery: inducing sterile inflammation in macrophages
44. Superparamagnetic iron oxide nanoparticles reprogram the tumor microenvironment and reduce lung cancer regrowth after crizotinib treatment10.1021/acsnano.3c08335 ↗
45. The use of iron oxide nanoparticles to reprogram macrophage responses and the immunological tumor microenvironment10.3389/fimmu.2021.693709 ↗
46. Interaction of iron oxide nanoparticles with macrophages is influenced distinctly by “self” and “non-self” biological identities10.1021/acsami.3c05555 ↗
47. Superparamagnetic nanoparticles as high efficiency magnetic resonance imaging T2 contrast agent10.1021/acs.bioconjchem.6b00577 ↗
48. Assessment of iron nanoparticle distribution in mouse models using ultrashort-echo-time MRI10.1002/nbm.4690 ↗
49. Magnetic, biocompatible FeCO3 nanoparticles for T2-weighted magnetic resonance imaging of in vivo lung tumors10.1186/s12951-022-01355-3 ↗
50. Relaxivity of Ferumoxytol at 1.5 T and 3.0 T, Invest
51. Uptake and metabolism of iron oxide nanoparticles in brain cells10.1007/s11064-014-1380-5 ↗
52. An immunohistochemical and morphometric study on astrocytes and microvas culature in the human cerebral cortex10.1023/A:1026448614647 ↗
53. Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)?10.1038/ki.2008.496 ↗
54. Early macrophage MRI of inflammatory lesions predicts lesion severity and disease development in relapsing EAE10.1016/j.neuroimage.2006.03.028 ↗
55. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment10.1016/j.cell.2018.05.060 ↗
56. Tumour-associated microglia/macrophages predict poor prognosis in high-grade gliomas and correlate with an aggressive tumour subtype10.1111/nan.12428 ↗
57. Distribution and prognostic impact of microglia/macrophage subpopulations in gliomas10.1111/bpa.12690 ↗
58. Highly sensitive imaging of tumor metastasis based on the targeting and polarization of M2-like macrophages10.1021/jacs.2c13218 ↗
59. Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-1010.1097/01.rli.0000101027.57021.28 ↗
60. In vivo non-invasive tracking of macrophage recruitment to experimental stroke
61. Negatively charged magnetite nanoparticle clusters as efficient MRI probes for dendritic cell labeling and in vivo tracking10.1002/adfm.201501031 ↗
62. Magnetic delivery of Fe3O4@polydopamine nanoparticle-loaded natural killer cells suggest a promising anticancer treatment10.1039/C8BM00588E ↗
63. Superparamagnetic iron oxide nanoparticles for direct labeling of stem cells and in vivo MRI tracking10.1002/cmmi.1658 ↗
64. Magnetic resonance imaging of tumor-associated macrophages: clinical translation10.1158/1078-0432.CCR-18-0673 ↗
65. Serum stability and affinity optimization of an M2 macrophage-targeting peptide (M2pep)10.7150/thno.15394 ↗
66. Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment10.1186/s13059-017-1362-4 ↗
67. Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target10.1038/s41467-022-28372-y ↗
68. Renal clearance of nanoparticles10.1038/nbt1340 ↗
69. Design considerations for tumour-targeted nanoparticles10.1038/nnano.2009.314 ↗
70. Ultrasmall Mn-doped iron oxide nanoparticles with dual hepatobiliary and renal clearances for T 1 MR liver imaging10.1039/D3NA00933E ↗
71. Gram-scale preparation of iron oxide nanoparticles with renal clearance properties for enhanced t 1-weighted magnetic resonance imaging10.1021/acsabm.8b00346 ↗
72. Ultrasmall cationic superparamagnetic iron oxide nanoparticles as nontoxic and efficient MRI contrast agent and magnetic-targeting tool
73. The journey of a drug-carrier in the body: an anatomo-physiological perspective10.1016/j.jconrel.2011.09.098 ↗
74. Anti-tumor macrophages activated by ferumoxytol combined or surface-functionalized with the TLR3 agonist poly (I: C) promote melanoma regression10.7150/thno.29746 ↗
75. SPION primes THP1 derived M2 macrophages towards M1-like macrophages10.1016/j.bbrc.2013.10.115 ↗
76. Ferumoxytol attenuates the function of MDSCs to ameliorate LPS-induced immunosuppression in sepsis10.1186/s11671-019-3209-2 ↗
77. Iron oxide nanoparticle-induced hematopoietic and immunological response in rats10.1039/D0RA05901C ↗
78. Hierarchically decorated magnetic nanoparticles amplify the oxidative stress and promote the chemodynamic/magnetic hyperthermia/immune therapy10.1016/j.actbio.2023.11.023 ↗
79. Controlled intracellular aggregation of magnetic particles improves permeation and retention for magnetic hyperthermia promotion and immune activation10.7150/thno.80821 ↗
80. Glucosylation endows nanoparticles with TLR4 agonist capability to trigger macrophage polarization and augment antitumor immunity10.1016/j.biomaterials.2023.122424 ↗